Back

Plasma amyloid-beta in relation to cardiac function and risk of heart failure in the general population

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Advances in ATTR amyloidosis Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Mrs Fang Zhu

Erasmus University Medical Centre, Rotterdam (Netherlands (The))

3 More presentations in this session

Presentation thumbnail
State-of-the-art lecture in ATTR amyloidosis.
Professor M. Fontana (London, GB)
Slides Video
Presentation thumbnail
Epidemiology of cardiac amyloidosis and burden on health care system in Germany: a retrospective analysis from 2009 to 2018
Associate Professor R. Pfister (Cologne, DE)
Abstract Slides Video
Presentation thumbnail
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis.
Doctor D. Tomasoni (Brescia, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Advances in ATTR amyloidosis
Video

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Plasma levels of amyloid beta 1-40 are associated with ultrasonographic morphological characteristics related with carotid plaque vulnerability in individuals without cardiovascular disease
thumbnail
Congress Presentation
Amyloid beta, a marker of vascular aging and cardiovascular disease, is associated with accelerated progression of renal dysfunction
thumbnail
Congress Presentation
Circulating Amyloid beta 1-40 is independently associated with statin treatment and LDL cholesterol reduction: a prospective cohort study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources